Oral stomatitis and mTOR inhibitors. A complete analysis of 21225 cases reported in literature

Arena, C.; Mascitti, M.; Troiano, G.; Lo Muzio, L.

Risultato della ricerca: Paper

Abstract

Traditional treatment of malignancies with chemotherapeutic agents is often affected by the damages inflicted on normal, healthy cells. Toxicities of the oral cavity, such as mucositis and stomatitis, are some of the most significant and unavoidable toxicities associated with anticancer therapies. For these reasons, everyone hoped in the newer targeted agents and their minor effects on normal, healthy cells. Unfortunately, targeted anti- cancer therapy can still cause significant toxicity to non-cancer cells. mTOR inhibitors have some adverse events, such as hyperglycemia, hyperlipidemia, hypophosphatemia, hematologic toxicities and mucocutaneous eruption, but the most important are still stomatitis and skin rash, often reported as dose-limiting side effect.
Lingua originaleEnglish
Stato di pubblicazionePublished - 2017

Cita questo

Oral stomatitis and mTOR inhibitors. A complete analysis of 21225 cases reported in literature. / Arena, C.; Mascitti, M.; Troiano, G.; Lo Muzio, L.

2017.

Risultato della ricerca: Paper

@conference{b539d75fd28e44cebc7a83cbf15bf97b,
title = "Oral stomatitis and mTOR inhibitors. A complete analysis of 21225 cases reported in literature",
abstract = "Traditional treatment of malignancies with chemotherapeutic agents is often affected by the damages inflicted on normal, healthy cells. Toxicities of the oral cavity, such as mucositis and stomatitis, are some of the most significant and unavoidable toxicities associated with anticancer therapies. For these reasons, everyone hoped in the newer targeted agents and their minor effects on normal, healthy cells. Unfortunately, targeted anti- cancer therapy can still cause significant toxicity to non-cancer cells. mTOR inhibitors have some adverse events, such as hyperglycemia, hyperlipidemia, hypophosphatemia, hematologic toxicities and mucocutaneous eruption, but the most important are still stomatitis and skin rash, often reported as dose-limiting side effect.",
author = "{Arena, C.; Mascitti, M.; Troiano, G.; Lo Muzio, L.} and Giuseppina Campisi",
year = "2017",
language = "English",

}

TY - CONF

T1 - Oral stomatitis and mTOR inhibitors. A complete analysis of 21225 cases reported in literature

AU - Arena, C.; Mascitti, M.; Troiano, G.; Lo Muzio, L.

AU - Campisi, Giuseppina

PY - 2017

Y1 - 2017

N2 - Traditional treatment of malignancies with chemotherapeutic agents is often affected by the damages inflicted on normal, healthy cells. Toxicities of the oral cavity, such as mucositis and stomatitis, are some of the most significant and unavoidable toxicities associated with anticancer therapies. For these reasons, everyone hoped in the newer targeted agents and their minor effects on normal, healthy cells. Unfortunately, targeted anti- cancer therapy can still cause significant toxicity to non-cancer cells. mTOR inhibitors have some adverse events, such as hyperglycemia, hyperlipidemia, hypophosphatemia, hematologic toxicities and mucocutaneous eruption, but the most important are still stomatitis and skin rash, often reported as dose-limiting side effect.

AB - Traditional treatment of malignancies with chemotherapeutic agents is often affected by the damages inflicted on normal, healthy cells. Toxicities of the oral cavity, such as mucositis and stomatitis, are some of the most significant and unavoidable toxicities associated with anticancer therapies. For these reasons, everyone hoped in the newer targeted agents and their minor effects on normal, healthy cells. Unfortunately, targeted anti- cancer therapy can still cause significant toxicity to non-cancer cells. mTOR inhibitors have some adverse events, such as hyperglycemia, hyperlipidemia, hypophosphatemia, hematologic toxicities and mucocutaneous eruption, but the most important are still stomatitis and skin rash, often reported as dose-limiting side effect.

UR - http://hdl.handle.net/10447/294475

M3 - Paper

ER -